Literature DB >> 17362993

The cerebral vasculopathy of Fabry disease.

David F Moore1, Christine R Kaneski, Hasan Askari, Raphael Schiffmann.   

Abstract

Fabry disease is an X-linked disorder affecting both males and females. It is associated with an increased risk of stroke in up to 4% of patients below 55 years of age in the general population. The cerebral vasculopathy consists of ischemic strokes involving large and small vessels. The neuronal accumulation of glycosphingolipids appears to have no clinical effect on the natural history of Fabry disease with the possible exception of some reported mild cognitive abnormalities. The pathogenesis of Fabry vasculopathy remains poorly understood but is associated with abnormal functional control of the vessel secondary to endothelial dysfunction, cerebral hyper-perfusion and a prothrombotic state with likely increased production of reactive oxygen species. These abnormalities are further modified by genetic and possibly other vascular risk factors. This vasculopathy illustrates the role of glycolipids in this and possibly other types of cerebral vasculopathies. Therapy is preventive relying on standard medical care and in particular on anti-platelet agents such as clopidogrel.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17362993     DOI: 10.1016/j.jns.2007.01.053

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  37 in total

Review 1.  Neurocutaneous Disorders for the Practicing Neurologist: a Focused Review.

Authors:  Anna Carolina Paiva Costa T Figueiredo; Nikolas Mata-Machado; Matthew McCoyd; José Biller
Journal:  Curr Neurol Neurosci Rep       Date:  2016-02       Impact factor: 5.081

2.  Cognitive function in adults aging with fabry disease: a case-control feasibility study using telephone-based assessments.

Authors:  Virginia G Wadley; Leslie A McClure; David G Warnock; Caroline L Lassen-Greene; Robert J Hopkin; Dawn A Laney; Virginia M Clarke; Manjula Kurella Tamura; George Howard; Katherine Sims
Journal:  JIMD Rep       Date:  2015-01-08

3.  Cognitive and psychological functioning in Fabry disease.

Authors:  Linda Sigmundsdottir; Michel C Tchan; Alex A Knopman; Graham C Menzies; Jennifer Batchelor; David O Sillence
Journal:  Arch Clin Neuropsychol       Date:  2014-11       Impact factor: 2.813

Review 4.  Stroke and Fabry disease.

Authors:  Miguel Viana-Baptista
Journal:  J Neurol       Date:  2011-10-27       Impact factor: 4.849

5.  Psychiatric and cognitive profile in Anderson-Fabry patients: a preliminary study.

Authors:  Perri Segal; Yoav Kohn; Yehuda Pollak; Gheona Altarescu; Esti Galili-Weisstub; Annick Raas-Rothschild
Journal:  J Inherit Metab Dis       Date:  2010-06-15       Impact factor: 4.982

6.  Diffusion tensor imaging and brain volumetry in Fabry disease patients.

Authors:  Teemu Paavilainen; Virva Lepomäki; Jani Saunavaara; Ronald Borra; Pirjo Nuutila; Ilkka Kantola; Riitta Parkkola
Journal:  Neuroradiology       Date:  2013-01-05       Impact factor: 2.804

7.  Vascular dysfunction in the alpha-galactosidase A-knockout mouse is an endothelial cell-, plasma membrane-based defect.

Authors:  James L Park; Steven E Whitesall; Louis G D'Alecy; Liming Shu; James A Shayman
Journal:  Clin Exp Pharmacol Physiol       Date:  2008-06-18       Impact factor: 2.557

Review 8.  Fabry disease: raising awareness of the disease among physicians.

Authors:  Francesca Carubbi; Lisa Bonilauri
Journal:  Intern Emerg Med       Date:  2012-10       Impact factor: 3.397

9.  Agalsidase alfa (Replagal) in the treatment of Anderson-Fabry disease.

Authors:  Gregory M Pastores
Journal:  Biologics       Date:  2007-09

10.  Globotriaosylceramide induces oxidative stress and up-regulates cell adhesion molecule expression in Fabry disease endothelial cells.

Authors:  Jin-Song Shen; Xing-Li Meng; David F Moore; Jane M Quirk; James A Shayman; Raphael Schiffmann; Christine R Kaneski
Journal:  Mol Genet Metab       Date:  2008-08-15       Impact factor: 4.797

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.